Thursday, May 14, 2026

Talcum Powder and Depo-Provera Dockets Dominate Daily Filings Amid 107-Case Wave

Federal dockets absorbed a concentrated 107 new mass-tort filings on Wednesday, driven heavily by legacy cosmetic claims and rapidly expanding pharmaceutical actions. The daily volume was anchored by the Johnson & Johnson Talcum Powder Litigation (MDL 2738) and the Depo-Provera Litigation (MDL 3140), demonstrating sustained momentum from the plaintiffs' bar across both mature and newly consolidated multidistrict proceedings.

The Johnson & Johnson Talcum Powder Litigation (MDL 2738) captured the largest share of the day's activity with 27 new complaints. These suits continue to press claims that the company’s iconic talc-based baby powder was tainted with asbestos, directly causing long-term users to develop ovarian cancer and mesothelioma. The relentless influx of new filings underscores a determination to maintain pressure on the manufacturer despite its ongoing efforts to resolve the sprawling docket through controversial bankruptcy maneuvers.

Tracking closely behind, the Depo-Provera Litigation (MDL 3140) recorded 21 new cases as plaintiffs’ counsel aggressively builds inventory. This pharmaceutical docket hinges on allegations that Pfizer’s blockbuster injectable contraceptive is directly linked to the development of meningiomas, leaving users with benign but severely debilitating brain tumors. As high-volume product liability dockets continue to attract tier-one plaintiffs' counsel, defense teams should anticipate an accelerated pace of discovery disputes and early bellwether maneuvering in the coming quarter.

Minnesota Sues 3M Over PFAS Contamination in Mississippi River

On May 14, 2026, a new lawsuit was initiated against 3M over alleged ongoing environmental damage from PFAS "forever chemicals" near the company's Cottage Grove facility in Minnesota. The state's environmental regulators claim that 3M's remediation efforts under a prior administrative order are incomplete and that its current groundwater extraction network is failing to prevent industrial and stormwater discharges into the Mississippi River. Testing at one location reportedly found PFOS levels as high as 310,000 parts per trillion, vastly exceeding the state's site-specific regulatory standard. Authorities are seeking civil penalties of up to $30,000 per violation per day, while 3M maintains it is on track to exit all PFAS manufacturing by the end of 2025 and has filed to move the case from state to federal court.

Doctrinal Divide Separates Talc Ovarian Cancer and Mesothelioma Resolutions

On May 14, 2026, a structural analysis highlighted the deepening procedural divide between ovarian cancer and mesothelioma claims within the broader Johnson & Johnson talc litigation. While both torts share a common defendant and product, mesothelioma cases are proceeding as individual trials because the disease is legally recognized as a "signature disease" for asbestos exposure. In contrast, the tens of thousands of ovarian cancer claims face higher Daubert admissibility risks due to their multi-factorial epidemiological nature, pushing them toward court-supervised mediation and aggregate resolution. This doctrinal divergence explains why the mesothelioma track resumed its established path after recent bankruptcy stays were lifted, while the massive ovarian cancer docket remains focused on securing a global matrix-based payout system.